Articles published by FSD Pharma Inc.

FSD Pharma Rebuts Claims of GBB Drink Lab now acquired by Jupiter Wellness Inc. Trading under the symbol (NASDAQ: JUPW)

August 25, 2023

Tickers CSE:HUGE HUGE

Arbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its Trial for FSD 201

July 17, 2023

From FSD Pharma Inc.

Via Business Wire

Tickers CSE:HUGE HUGE

FSD Pharma Retains Christian Attar Law and Team of Experts to Lead Preliminary Investigation of Possible Naked Short Selling and Manipulation in its stock

July 10, 2023

From FSD Pharma Inc.

Via Business Wire

Tickers CSE:HUGE HUGE

FSD Pharma Appoints Zeeshan Saeed as Chief Executive Officer, Anthony Durkacz to Serve as Executive Co-Chairman of the Board of Directors

July 04, 2023

From FSD Pharma Inc.

Via Business Wire

Tickers CSE:HUGE HUGE

FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders

June 30, 2023

From FSD Pharma Inc.

Via Business Wire

Tickers CSE:HUGE HUGE

FSD Pharma Announces Agreement to Grant Exclusive Rights to Revolutionary Recreational Alcohol Misuse Technology

June 20, 2023

From FSD Pharma Inc.

Via Business Wire

Tickers CSE:HUGE HUGE

FSD Pharma Appoints Former Ontario Minister of Health Doctor Eric Hoskins to Board of Directors

May 25, 2023

From FSD Pharma Inc.

Via Business Wire

Tickers CSE:HUGE HUGE

FSD Pharma Announces Receipt of Court Action and Update on Spin-Out and Distribution

May 12, 2023

From FSD Pharma Inc.

Via Business Wire

Tickers CSE:HUGE HUGE

FSD Pharma Awarded $2.81 Million in Cost Awards From Dr. Raza Bokhari

May 11, 2023

From FSD Pharma Inc.

Via Business Wire

Tickers CSE:HUGE HUGE

FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort

May 10, 2023

From FSD Pharma Inc.

Via Business Wire

Tickers CSE:HUGE HUGE

FSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11

May 08, 2023

From FSD Pharma Inc.

Via Business Wire

Tickers CSE:HUGE HUGE

FSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis

April 17, 2023

From FSD Pharma Inc.

Via Business Wire

Tickers CSE:HUGE HUGE

FSD Pharma Announces Plan to Spin-Out Subsidiary as Distribution to Shareholders; Shareholder Meeting Scheduled for June 29, 2023

April 12, 2023

From FSD Pharma Inc.

Via Business Wire

Tickers CSE:HUGE HUGE

FSD Pharma Announces Filing of Year-End 2022 Results

March 31, 2023

From FSD Pharma Inc.

Via Business Wire

Tickers CSE:HUGE HUGE

FSD Pharma Adds Former Celsius Holdings CEO Gerry David to Board of Advisors

March 30, 2023

From FSD Pharma Inc.

Via Business Wire

Tickers CSE:HUGE HUGE

FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder

March 22, 2023

From FSD Pharma Inc.

Via Business Wire

Tickers CSE:HUGE HUGE

FSD Pharma (Symbol: HUGE) Renews Shareholder Intelligence Services to Investigate Possible Naked Short Selling and Appeals to The Regulators and Oversight Bodies to Look Into The Short Selling Activity Of Its Stock

March 14, 2023

From FSD Pharma Inc.

Via Business Wire

Tickers CSE:HUGE HUGE

Original “Shark” and Iconic Entrepreneur Kevin Harrington Joins FSD Pharma Advisory Board

February 28, 2023

From FSD Pharma Inc.

Via Business Wire

Tickers CSE:HUGE HUGE

FSD Pharma Presenting Two Scientific Posters on Preclinical Toxicology and Efficacy Data of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2023 Forum

February 21, 2023

From FSD Pharma Inc.

Via Business Wire

Tickers CSE:HUGE HUGE

FSD Pharma Regains Compliance with NASDAQ Continued Listing Requirements

February 15, 2023

From FSD Pharma Inc.

Via Business Wire

Tickers CSE:HUGE HUGE

FSD Pharma Launches A New Research and Development Program Targeting Unmet Medical Needs for Alcohol Misuse

February 14, 2023

From FSD Pharma Inc.

Via Business Wire

Tickers CSE:HUGE HUGE

FSD Pharma Receives Regulatory Clearance for Its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug Candidate

February 07, 2023

From FSD Pharma Inc.

Via Business Wire

Tickers CSE:HUGE HUGE

Recruiting Underway in FSD Pharma’s Phase 2 Trial of FSD-PEA (FSD201) for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)

January 30, 2023

From FSD Pharma Inc.

Via Business Wire

Tickers CSE:HUGE HUGE

FSD Pharma submits its phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigation

January 17, 2023

From FSD Pharma Inc.

Via Business Wire

Tickers CSE:HUGE HUGE

FSD Pharma Announces Share Repurchase Program

January 13, 2023

From FSD Pharma Inc.

Via Business Wire

Tickers CSE:HUGE HUGE

FSD Pharma Inc Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia

January 09, 2023

From FSD Pharma Inc.

Via Business Wire

Tickers CSE:HUGE HUGE

FSD Pharma to Attend 41st Annual J.P. Morgan Healthcare Conference 2023

January 06, 2023

From FSD Pharma Inc.

Via Business Wire

Tickers CSE:HUGE HUGE

FSD Pharma Announces Changes to the Board of Directors

November 28, 2022

From FSD Pharma Inc.

Via Business Wire

Tickers CSE:HUGE HUGE

FSD Pharma Announces Arbitrator Dismisses Claims by Former CEO, Dr. Raza Bokhari

November 10, 2022

From FSD Pharma Inc.

Via Business Wire

Tickers CSE:HUGE HUGE

FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

September 29, 2022

From FSD Pharma Inc.

Via Business Wire

Tickers CSE:HUGE HUGE

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.